Specific Biomarkers for Detection of Cervical Cancer Cells Using Flow Cytometry

宫颈癌是仅次于乳腺癌的最常见的恶性肿瘤，在发病率和 世界各地妇女的死亡率。纸片涂片试验和液基细胞学已被采用为 美国和其他发达国家的全人口宫颈癌筛查计划。在美国， 这项筛查计划显著降低了子宫颈癌的发病率和死亡率。 癌症，从1941年的26,000人增加到2000年的4,600人。然而，目前宫颈癌筛查的方法是 从大量正常细胞中检测异常细胞仍然具有主观性和劳动强度。这 应用提出了一种涉及特定生物标志物和高通量流式细胞术的新方法 罕见异常细胞的检测。异常细胞将被捕获并与正常细胞分离 根据其癌前生物标记物的表达水平进行流动分类。这方面的发展 技术可能导致高通量、生物标记物驱动的常规宫颈癌临床设备 未来的放映。

Cervical cancer is second to breast cancer as the most common form of malignancy in both incidence and mortality for women worldwide. The pap smear test and liquid-based cytology have been adopted as population-wide cervical cancer screening programs in the U.S.and other developed countries. In the US, this screening program has led to a remarkable reduction in the incidence and mortality rate of cervical cancer, from 26,000 in 1941 to 4,600 in 2000. However, the current method of cervical cancer screening is still subjective and labor intensive in the detection of abnormal cells from large number of normal cells. This application proposes a new approach of involving specific biomarkers and high throughput flow cytometry for the detection of rare abnormal cells. Abnormal cells will be captured and separated from normal cells using flow sorting and based on their expression levels of precancerous biomarkers. The development of this technology could lead to a high throughput, biomarker driven clinical device for routine cervical cancer screening in the future.